Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 81

1.

Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial.

Cabanillas ME, Kantarjian H, Thomas DA, Mattiuzzi GN, Rytting ME, Bruera E, Xiao L, Bekele BN, Foudray MC, Cortes JE.

Cancer. 2012 Feb 1;118(3):848-55. doi: 10.1002/cncr.26341. Epub 2011 Jul 12.

2.

Assessing the effect of darbepoetin alfa on patient-reported fatigue in chemotherapy-induced anemia in four randomized, placebo-controlled clinical trials.

Revicki DA, Stull D, Vernon M, Rader M, Tomita D, Viswanathan HN.

Qual Life Res. 2012 Mar;21(2):311-21. doi: 10.1007/s11136-011-9946-z. Epub 2011 Jun 5.

PMID:
21644007
3.

Addition of darbepoetin alfa to dose-dense chemotherapy: results from a randomized phase II trial in small-cell lung cancer patients receiving carboplatin plus etoposide.

Nagel S, Kellner O, Engel-Riedel W, Guetz S, Schumann C, Gieseler F, Schuette W.

Clin Lung Cancer. 2011 Jan;12(1):62-9. doi: 10.3816/CLC.2011.n.009.

PMID:
21273182
4.

Drug therapy for the management of cancer-related fatigue.

Minton O, Richardson A, Sharpe M, Hotopf M, Stone P.

Cochrane Database Syst Rev. 2010 Jul 7;(7):CD006704. doi: 10.1002/14651858.CD006704.pub3. Review.

PMID:
20614448
5.
6.

Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial.

Vansteenkiste J, Hedenus M, Gascon P, Bokemeyer C, Ludwig H, Vermorken J, Hamilton L, Bridges K, Pujol B.

BMC Cancer. 2009 Sep 3;9:311. doi: 10.1186/1471-2407-9-311.

7.

Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data.

Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke MJ, Weingart O, Kluge S, Piper M, Napoli M, Rades D, Steensma D, Djulbegovic B, Fey MF, Ray-Coquard I, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A.

Cochrane Database Syst Rev. 2009 Jul 8;(3):CD007303. doi: 10.1002/14651858.CD007303.pub2. Review.

PMID:
19588423
8.

Randomized, double-blind, placebo-controlled trial of epoetin alfa in men with castration-resistant prostate cancer and anemia.

Winquist E, Julian JA, Moore MJ, Nabid A, Sathya J, Wood L, Venner P, Levine M.

J Clin Oncol. 2009 Feb 1;27(4):644-6. doi: 10.1200/JCO.2008.20.4966. Epub 2008 Dec 22. No abstract available.

PMID:
19103725
9.

[Study of effectiveness of 3 schedules of administration of erythropoietic colony-stimulating factors in anemic patients under chemotherapy for solid or hematology malignancy].

Pontón Sivillá JL, Feliu Frasnedo E, Modamio Charles P, Mariño Hernández EL, Font Pous A, Lezcano Rubio C, Ribera Santasusana JM, Bonafont Pujol X.

Med Clin (Barc). 2008 Oct 11;131(12):447-51. Spanish.

PMID:
18928734
10.

Epoetin delta: efficacy in the treatment of anaemia in cancer patients receiving chemotherapy.

Krzakowski M; DYNEPO Oncology Study Group..

Clin Oncol (R Coll Radiol). 2008 Nov;20(9):705-13. doi: 10.1016/j.clon.2008.06.001. Epub 2008 Aug 8.

PMID:
18691854
11.
12.

Development of a fatigue and functional impact scale in anemic cancer patients receiving chemotherapy.

Cella D, Viswanathan HN, Hays RD, Mendoza TR, Stein KD, Pasta DJ, Foreman AJ, Vadhan-Raj S, Kallich JD.

Cancer. 2008 Sep 15;113(6):1480-8. doi: 10.1002/cncr.23698.

13.

Treating anemia of cancer with every-4-week darbepoetin alfa: final efficacy and safety results from a phase II, randomized, double-blind, placebo-controlled study.

Gordon D, Nichols G, Ben-Jacob A, Tomita D, Lillie T, Miller C.

Oncologist. 2008 Jun;13(6):715-24. doi: 10.1634/theoncologist.2007-0241.

14.

Erythropoiesis-stimulating agents in cancer.

Arcasoy MO.

J Clin Oncol. 2008 Jun 20;26(18):3097-8; author reply 3098-100. doi: 10.1200/JCO.2008.16.0531. No abstract available.

PMID:
18565902
15.

Effect of epoetin on survival in patients with breast cancer.

Codacci-Pisanelli G, Spinelli GP, Tomao S.

J Clin Oncol. 2008 May 20;26(15):2599; author reply 2599-600. doi: 10.1200/JCO.2008.16.7262. No abstract available.

PMID:
18487580
16.

Weekly epoetin beta maintains haemoglobin levels and improves quality of life in patients with non-myeloid malignancies receiving chemotherapy.

Suzuki Y, Tokuda Y, Fujiwara Y, Minami H, Ohashi Y, Saijo N.

Jpn J Clin Oncol. 2008 Mar;38(3):214-21. doi: 10.1093/jjco/hyn002. Epub 2008 Feb 21.

PMID:
18296425
17.

Dosing and Outcomes Study of Erythropoiesis-Stimulating Therapies (DOSE) : a registry for characterizing anaemia management and outcomes in oncology patients.

Larholt K, Pashos CL, Wang Q, Bookhart B, McKenzie RS, Piech CT.

Clin Drug Investig. 2008;28(3):159-67.

PMID:
18266401
18.

Survival and erythropoietin receptor protein in tumours from patients randomly treated with rhEPO for palliative care.

Lönnroth C, Svensson M, Wang W, Körner U, Daneryd P, Nilsson O, Lundholm K.

Med Oncol. 2008;25(1):22-9. doi: 10.1007/s12032-007-9001-7. Epub 2007 Sep 11.

PMID:
18188711
20.

Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.

Voravud N, Sriuranpong V, Suwanrusme H.

J Med Assoc Thai. 2007 Jun;90(6):1082-8.

PMID:
17624200

Supplemental Content

Support Center